JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

MeSH: chelátory železa-aplikace a dávkování

35 záznamů v Články Filtry

Článek

Trial of Deferiprone in Parkinson's Disease

Devos, David
Autor Devos, David From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Labreuche, Julien
Autor Labreuche, Julien From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Rascol, Olivier
Autor Rascol, Olivier From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Corvol, Jean-Christophe
Autor Corvol, Jean-Christophe From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Duhamel, Alain
Autor Duhamel, Alain From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Guyon Delannoy, Pauline
Autor Guyon Delannoy, Pauline From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Poewe, Werner
Autor Poewe, Werner From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Compta, Yaroslau
Autor Compta, Yaroslau From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Pavese, Nicola
Autor Pavese, Nicola From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Růžička, Evžen
Autor Růžička, Evžen From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)

The New England journal of medicine. 2022 ; 387 (22) : 2045-2055. [pub] 2022Dec01

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. METHODS: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. RESULTS: A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P<0.001). Nigrostriatal iron content decreased more in the deferiprone group than in the placebo group. The main serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 participants. CONCLUSIONS: In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks. (Funded by the European Union Horizon 2020 program; FAIRPARK-II ClinicalTrials.gov number, NCT02655315.).

Článek

Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy

Cancer research. 2021 ; 81 (9) : 2289-2303. [pub] 20210308

Cancer Res
ISSN 1538-7445
Medvik
Zdroj

Deferoxamine (DFO) represents a widely used iron chelator for the treatment of iron overload. Here we describe the use of mitochondrially targeted deferoxamine (mitoDFO) as a novel approach to preferentially target cancer cells. The agent showed marked cytostatic, cytotoxic, and migrastatic properties in vitro, and it significantly suppressed tumor growth and metastasis in vivo. The underlying molecular mechanisms included (i) impairment of iron-sulfur [Fe-S] cluster/heme biogenesis, leading to destabilization and loss of activity of [Fe-S] cluster/heme containing enzymes, (ii) inhibition of mitochondrial respiration leading to mitochondrial reactive oxygen species production, resulting in dysfunctional mitochondria with markedly reduced supercomplexes, and (iii) fragmentation of the mitochondrial network and induction of mitophagy. Mitochondrial targeting of deferoxamine represents a way to deprive cancer cells of biologically active iron, which is incompatible with their proliferation and invasion, without disrupting systemic iron metabolism. Our findings highlight the importance of mitochondrial iron metabolism for cancer cells and demonstrate repurposing deferoxamine into an effective anticancer drug via mitochondrial targeting. SIGNIFICANCE: These findings show that targeting the iron chelator deferoxamine to mitochondria impairs mitochondrial respiration and biogenesis of [Fe-S] clusters/heme in cancer cells, which suppresses proliferation and migration and induces cell death. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/9/2289/F1.large.jpg.

MeSH
buněčná smrt účinky léků MeSH
buňky PC-3 MeSH
chelátory železa aplikace a dávkování MeSH
deferoxamin aplikace a dávkování MeSH
hem metabolismus MeSH
karcinogeneze účinky léků MeSH
lidé MeSH
MFC-7 buňky MeSH
mitochondrie účinky léků metabolismus MeSH
mitofagie účinky léků MeSH
myši inbrední BALB C MeSH
myši MeSH
nádory farmakoterapie metabolismus patologie MeSH
pohyb buněk účinky léků MeSH
proliferace buněk účinky léků MeSH
reaktivní formy kyslíku metabolismus MeSH
signální transdukce účinky léků MeSH
tumor burden účinky léků MeSH
xenogenní modely - testy antitumorózní aktivity MeSH
železo metabolismus MeSH
zvířata MeSH
Check Tag
lidé MeSH
myši MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH

Článek

Možnosti léčby anemie u pacientů s myelodysplastickým syndromem nízkého rizika
[Treatment options for anemia in patients with low‑risk myelodysplastic syndrome]

Bělohlávková, Petra
Autor Autorita IV. interní hematologická klinika LF UK a FN, Hradec Králové

Onkologická revue. 2020 ; 7 (4) : 64-69.

ISSN 2464-7195
Medvik
Zdroj

Prognóza a léčba pacientů s myelodysplastickým syndromem (MDS) je závislá na stanovení rizika podle IPSS (International Prognostic Scoring System) či jeho revidované formy IPSS-R, které rozdělí pacienty do skupiny nižšího a vyššího rizika choroby. Riziko transformace do akutní myeloidní leukemie je závažný problém u pacientů vysokého rizika, zatímco anemie představuje dominující problém u MDS pacientů nízkého rizika. Zlepšení erytropoézy a odstranění symptomů anemie představuje hlavní léčebný cíl u této skupiny pacientů. Přípravky stimulující erytropoézu dosahují léčebné odpovědi asi u 50 % pacientů, avšak medián trvání léčebné odpovědi je pouze 15-18 měsíců. Léčba lenalidomidem je určena pro pacienty s delecí dlouhého raménka 5. chromosomu (u tzv. MDS 5qsyndromu). Erytrocytární odpovědi zde bývá dosaženo až u 70-80 % pacientů a dosažení transfuzní závislosti je přítomno u 60-70 % pacientů. Nově schváleným přípravkem v letošním roce je luspatercept, který je účinný především u forem MDS s prstenčitými sideroblasty či mutací genu SF3B1. Roxadustat a imetelstat se jeví jako nadějné přípravky k léčbě anemie u MDS pacientů nízkého rizika.

The prognosis and treatment patients with myelodysplastic syndrome (MDS) depend on the conventional determination of IPSS (International Prognostic Scoring System) or its revised form IPSS-R, which divide patients into lower and higher risk groups. The risk of transformation into acute myeloid leukemia is a major problem in high-risk patients, while anemia represents the major issues for low-risk MDS patients. Improving erythropoiesis and eliminating the symptoms of anemia is a major therapeutic goal in this group of patients. Treatment by erythropoiesis-stimulating agents achieves a response rate in 50% of patients, but the median duration of response is between 15 to 18 months. Therapy by lenalidomide is indicated in patients with deletion 5 chromosome (MDS 5qsyndrome). The erythrocyte response is usually achieved in 70-80% of patients and the achievement of transfusion dependence occurs in 60-70% of patients. The newly approved drug this year is luspatercept, which is especially effective in forms of MDS with ring sideroblasts or SF3B1 mutation. Roxadustat and imetelstat are promising drugs for the treatment of anemia in low-risk MDS patients.

Článek

Optimální léčebné postupy u pacientů s myelodysplastickým syndromem
[Optimal treatment approaches for patients with myelodysplastic syndrome]

Onkologická revue. 2017 ; 2017 (2) : 17-26.

ISSN 2464-7195
Medvik
Zdroj

Myelodysplastický syndrom je klonální onemocnění kostní dřeně způsobené poškozením genetické informace myeloidní kmenové buňky. Představuje heterogenní skupinu onemocnění charakterizovanou inefektivní hematopoezou s dysplazií jedné či více myeloidních linií vedoucí k cytopenii (či cytopeniím) a s vysokou incidencí progrese do akutní myeloidní leukémie (asi v jedné třetině případů). V krevním obraze se nejčastěji vyskytuje anémie, a to buď samostatně, nebo v kombinaci s trombocytopenií či leukopenií, neutropenií. Klinické příznaky odpovídají typu a hloubce dané cytopenie – anemický syndrom, krvácivé projevy u trombocytopenie nebo infekční komplikace při neutropenii. Myelodysplastický syndrom je onemocnění vyskytující se téměř výhradně u pacientů staršího věku (nejčastější výskyt je mezi 65–70 lety) s incidencí 3–5 nových případů na 100 000 obyvatel ročně. Incidence rychle narůstá s věkem a ve skupině obyvatel nad 70 let dosahuje 20–40 nových případů na 100 000 obyvatel. Myelodysplastický syndrom je diagnostikován jako primární – v případě nejasné etiologie, nebo sekundární – často po předchozí chemoterapii nebo radioterapii pro jiné nádorové onemocnění či po expozici známé toxické noxe.

Myelodysplastic syndrome is a clonal disorder of the bone marrow caused by damage to the genetic information myeloid stem cell. It represents a heterogeneous group of disorders characterized by ineffective hematopoiesis with dysplasia of one or more myeloid lineage leading to cytopenia (or cytopenias) and the high incidence of progression to acute myeloid leukemia (about 1/3 cases). The blood count is most prevalently represented by anemia alone, in combination with thrombocytopenia or leucopenia, neutropenia. Clinical symptoms are consistent with the type and depth of the cytopenia – anemic syndrome, bleeding manifestation from thrombocytopenia or infectious complications in neutropenic patients. Myelodysplastic syndrome is a disease occurring almost solely in patients of older age (most frequent occurrence between 65–70 years), with an incidence of 3–5 new cases per 100,000 population per year. The incidence of myelodysplastic syndrome increases with age rapidly and in a group of people over 70 years amounts to 20 to 40 new cases per 100,000 inhabitants. Myelodysplastic syndrome is diagnosed as in the case of primary – unknown etiology, or secondary – often after chemotherapy or radiotherapy for an other cancer or after exposure to a known toxic agent.

Článek

Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone

Canadian journal of cardiology. 2016 ; 32 (12) : 1574.e1-1574.e3. [pub] 20160728

Can J Cardiol
ISSN 1916-7075
Medvik
Zdroj

There is scarce evidence regarding the use of iron chelators in patients with hereditary hemochromatosis who are intolerant of phlebotomy or erythrocytapheresis. A 52-year-old man with genetically confirmed HFE hemochromatosis presented with liver disease and heart failure with severe left ventricular systolic dysfunction. Because of anemia after initial treatment, we added intravenous deferoxamine followed by oral deferiprone to less frequent erythrocytapheresis, which normalized systolic function within 1 year. Repeated cardiac magnetic resonance imaging revealed improvement of the T2* relaxation time. This report illustrates the beneficial effect of iron chelators in individuals with HFE hemochromatosis and poor tolerance of erythrocytapheresis.

Článek

Nové možnosti v léčbě myelodysplastického syndromu
[New options in the treatment of myelodysplastic syndromes]

Onkologie (Olomouc, Print). 2014 ; 8 (1) : 28-33.

Onkologie (Olomouc Print)
ISSN 1802-4475
Medvik
Zdroj

Myelodysplastický syndrom (MDS) je heterogenní skupina klonálních onemocnění krvetvorné kmenové buňky, která se vyznačuje dysplastickými změnami prekursorů v kostní dřeni, periferní (pan) cytopenií a zvýšeným rizikem progrese do akutní myeloidní leukemie (AML). V terapii MDS byly dlouhodobě využívány především dvě základní modality: podpůrná péče nebo alogenní transplantace krvetvorných kmenových buněk (ASCT). V poslední době se však léčebné možnosti pro MDS nemocné významně rozšířily. Vedle konvenčně používané terapie se objevily nové léky a jejich kombinace, které mohou ovlivnit přirozený průběh choroby a prodloužit přežití. V klinické praxi nacházejí největší uplatnění hypometylační látky, imunomodulans lenalidomid (LEN) a moderní chelátory.

Myelodysplastic syndromes (MDS) are heterogeneous group of clonal hematopoietic stem cell disorders characterized by dysplastic changes of bone marrow precursors, peripheral (pan) cytopenias and an increased risk of progression to acute myeloid leukemia (AML). Two basic therapeutic approaches were used in the treatment of MDS: supportive care or allogeneic stem cell transplantation (ASCT). Nowadays the treatment options for MDS patients has significantly expanded. In addition to conventional treatment there are new drugs and their combinations which may affect the natural history of the disease and prolong survival. In the clinical practice hypometylating agents, immunomodulatory drug lenalidomide (LEN) and modern chelators are used.

Článek

Terapie pacientky s myelodysplastickým syndromem s přetížením železem perorálním chelátorem deferasiroxem

Jonášová, Anna
Autor Autorita ORCID

Farmakoterapie. 2010 ; 6 (3) : 263-266.

Medvik
Zdroj

Myelodysplastický syndrom (MDS) je heterogenní skupina onemocnění, pro něž je charakteristická diskrepance mezi bohatou krvetvorbou a periferní pancytopenií jako následek neefektivní hematopoezy s klinickými projevy anemie, infekce a krvácením. Možná je transformace do akutní leukemie. U pacientů s MDS rozlišujeme vysoce a nízce rizikové MDS s použitím mezinárodního prognostického skórovacího systému IPSS (International Prognostic Scoring System), nověji WPSS (WHO-based Prognostic Scoring System). Nízce rizikoví nemocní jsou pacienti s pravděpodobným dlouhodobým přežíváním (10 i více let). Hlavním problémem těchto nemocných je více či méně symptomatická anemie – přes 90 % nemocných s MDS trpí anemií, z toho 50–60 % má anemii těžkou. Téměř 80 % pacientů v průběhu svého onemocnění dostává krevní převody a asi u 40 % nemocných jsou bohužel transfuze jedinou možnou terapií. Každá transfuzní jednotka (TU) představuje přísun asi 200–250 mg železa (Fe), což při denní exkreci Fe asi 1–2 mg a nutnosti opakovaných převodů krve vede nevyhnutelně k hromadění Fe v organismu. Na kumulaci Fe u MDS se navíc spoluúčastní i zvýšená resorpce jako nespecifická reakce při refrakterní anemii a nadměrné uvolňování Fe z buněk při neefektivní erytropoeze. Nadbytečné intracelulární Fe vede k tvorbě vysoce reaktivních hydroxylových radikálů, které mohou způsobit oxidativní poškození lipidů, proteinů, molekul DNA a vést až ke smrti buňky. Fe se hromadí v orgánech s jejich následným poškozením, vedoucím v některých případech až k selhání jejich funkcí. Přetížení Fe způsobuje u pacientů s MDS nejen zkrácení celkového přežití, ale i zhoršení výsledků alogenních transplantací se zvýšenou peritransplantační mortalitou.1–4 Chelatace je zatím jedinou prevencí a terapií nadbytečné akumulace Fe v organismu. Chelátory snižují množství tkáňového Fe, zabraňují jeho akumulaci a neutralizují toxické labilní plazmatické Fe (LPI – labile plasma iron).5 Chelatační terapie u nemocných závislých na transfuzích se stává jejich chronickou medikací, a je proto nutné, aby byla dobře snášena, jednoduše aplikovatelná, s co nejmenším množstvím komplikací a minimální toxicitou. V roce 2008 byl uveden na náš trh nový chelátor deferasirox (Exjade). Deferasirox je perorální chelátor s prodlouženým plazmatickým poločasem, umožňujícím účinnou chelataci po dobu 24 hodin a aplikaci 1x denně. Účinná dávka vedoucí ke snížení celkového Fe v organismu je kolem 20–30 mg/kg/den. Tento lék je dobře snášen, s většinou únosnými gastrointestinálními obtížemi (nauzea, průjem, bolesti břicha).6,7 Opatrnosti je třeba pro možný rozvoj známek poruch renálních funkcí, často pouze reverzibilních.

MeSH
chelátory železa aplikace a dávkování MeSH
ferritin krev metabolismus MeSH
ischemická choroba srdeční farmakoterapie MeSH
krevní transfuze využití MeSH
lidé MeSH
myelodysplastické syndromy klasifikace terapie MeSH
poruchy metabolismu železa farmakoterapie MeSH
potransfuzní reakce MeSH
senioři MeSH
železo krev škodlivé účinky MeSH
Check Tag
lidé MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
kazuistiky MeSH

Článek

Současný přístup k léčbě přetížení železem

Pospíšilová, Dagmar
Autor Autorita ORCID

Farmakoterapie. 2010 ; 6 (1) : 84-91.

Medvik
Zdroj

Železo (Fe) je základní složkou hemoglobinu a myoglobinu, a má proto nezastupitelnou funkci v přenosu kyslíku. Je také kofaktorem důležitých enzymů: kataláz, ribonukleotidreduktáz, peroxidáz, cytochromoxidáz, akonitáz. Tyto enzymy katalyzují řadu chemických reakcí důležitých pro přežití organismu, jako je mitochondriální respirace či syntéza nukleových kyselin (DNA i RNA) a důležitých proteinů, a účastní se buněčné proliferace, diferenciace a apoptózy.1 Je tedy prvkem zcela nezbytným pro život. Jak nedostatek Fe, tak i jeho nadbytek je pro organismus škodlivý. Při nedostatku železa dochází k rozvoji sideropenické anemie, která je poměrně snadno léčitelná. Nadbytečná akumulace železa představuje ve svých důsledcích mnohem závažnější ohrožení než jeho nedostatek.

Článek

Novinky v terapii nízce rizikových nemocných s myelodysplastickým syndromem
[Novel aproaches in therapy of low-risk patients with myelodysplastic syndrome]

Jonášová, Anna
Autor Autorita ORCID

Transfuze a hematologie dnes. 2009 ; 15 (2) : 114-120.

ISSN 1213-5763
Medvik
Zdroj

Myelodysplastický syndrom patří mezi nejčastější hematologická onemocnění. Jeho incidence stále narůstá s prodlužujícím se věkem populace a pravděpodobně též se zvyšováním expozice různým toxickým látkám. Terapie tohoto onemocnění je však stále svízelná. Z pohledu terapie nejčastěji dělíme MDS na nízce a vysoce rizikové nemocné. V našem přehledném článku se zabýváme některými novými terapeutickými přístupy a preparáty používanými u nízce rizikových nemocných též s ohledem k tomu, že v dohledné době by měly být k dispozici i pro naše nemocné. Na prvém místě jmenujeme růstové faktory, zvláště pak erytropoézu stimulující proteiny, zásady terapie pramenící z dosavadních klinických studií a nové preparáty. Dále se věnujeme přehledu chelatační terapie s novými guidelines a stručně i výsledkům vlastních zkušeností. Následují informace o zcela nových úspěšných terapeutických přístupech a to použití imunomodulační a demetylační terapie s popisem preparátů. V neposlední řadě pak je zmiňována již známá imunosupresivní terapie, ale se stále jasnějšími kritériemi selekce nemocných.

Myelodysplastic syndrome is one of the most frequent haematological diseases. Its incidence is on the rise due to the increasing life expectancy of the population and also probably due to the increasing exposure to various toxic substances. Treatment of this disease, though, remains difficult. In terms of therapy, we most frequently divide MDS into low and very high-risk patients. In our review, we deal with some of the novel therapeutic approaches and preparations used in the low risk patients, also taking into account that these should become available to our patients in the foreseeable future. We first focus on growth factors, especially erythropoiesis stimulating proteins, and the fundamentals of treatment based on current clinical trials and new preparations. We then present an overview of chelation therapy, including new guidelines and a brief summary of our own results and experience. This is followed by information regarding completely novel and successful therapeutic approaches, namely the use of immunomodulatory and demethylation therapy, and a description of these preparations. Last but not least, we will direct our attention to immunosuppressive therapy, an already well-known modality, yet with clearer criteria of patient selection.

Článek

Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity

Hemoglobin. 2008 ; 32 (1-2) : 207-215.

ISSN 0363-0269
Medvik
Zdroj

The risk of cardiotoxicity is the main drawback of anthracycline antibiotics. However, these drugs remain among the most effective and frequently used anti cancer drugs. In this study we aimed to assess the cardioprotective effects of aroylhydrazone iron (FE) chelators: pyridoxal isonicotinoyl hydrazone (PIH) and its two analogs: salicyladehyde isonicotinoyl hydrazone (SIH) and pyridoxal o-chlorbenzoyl hydrazone (o-108). In rabbits, chronic treatment with daunorubicin (DAU) (3 mg/kg weekly for 10 weeks) induced mortality (33%) as well as left ventricular (LV) dysfunction. Co-administrations of PIH (25 mg/kg, i.p.), SIH hydrochloride [1 mg/kg, iv] as well as o-108 (10 mg/kg, i.p.), fully prevented premature deaths and most of the DAU-induced functional impairments were significantly suppressed. However, when 2- to 2.5-fold higher doses of the chelators were used, they led to rather paradoxical and mostly negative results regarding both cardioprotection and overall mortality.

Kolekce

Publikováno

Filtry

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH